Marc N. Wagner


Washington, D.C.
T +1.202.861.1557
F +1.202.861.1783


Marc Wagner’s knowledge of pharmaceutical compliance adds value to his developing practice. He has experience interpreting FDA guidance documents, prescription drug monitoring programs, Investigational New Drug Application requirements, and state board of pharmacy rules and regulations. Additionally, Marc’s educational and professional background in pharmacy provides him with a substantial understanding of a variety of pharmaceutical compliance measures, including pharmaceutical compounding, 503B outsourcing facilities, pharmacy reimbursement, FDA labeling requirements, and Drug Enforcement Administration requirements. This background enables Marc to assist with due diligence in life science transactions and navigate federal and state licensing for drug manufacturers, wholesale distributors, pharmacies, and outsourcing facilities.

Recognitions and Memberships


  • Food and Drug Law Institute, New to Food and Drug Law (NFDL) Planning Committee
  • American Society for Pharmacy Law





  • Catholic Charities Legal Network

Prior Positions

  • Drug Enforcement Administration, Office of Chief Counsel, Diversion and Regulatory Policy Section: Intern
  • Food and Drug Administration, Office of Policy: Intern
  • BakerHostetler: Summer Associate
  • Pharmacist in national retail pharmacy setting


  • Pennsylvania
  • District of Columbia


  • J.D., The Pennsylvania State University - Dickinson Law, 2019; Dickinson Law Review Articles Editor; CALI Award, Health Care Law & Policy, Health Care Innovation & Entrepreneurship
  • Certificate in Corporate Compliance with a Concentration in Health Care, The Pennsylvania State University - Dickinson Law, 2019
  • M.B.A., The Pennsylvania State University, 2019
  • Pharm.D., University of the Sciences, Philadelphia College of Pharmacy, 2016, cum laude
  • B.S., Pharmaceutical and Healthcare Studies, University of the Sciences, Philadelphia College of Pharmacy, 2014, cum laude


In The Blogs

Previous Next
IP Intelligence: Insight on Intellectual Property
Considerations for 3D Printing of Medical Devices, Accessories, Components and Parts During the COVID-19 Pandemic
By Lee H. Rosebush, Marc N. Wagner
April 13, 2020
The medical device industry and the Food and Drug Administration (FDA) have been experimenting with three-dimensional (3D) printing for years. Shortages of medical devices such as personal protective equipment (PPE) and ventilators abound...